GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » China NT Pharma Group Co Ltd (HKSE:01011) » Definitions » Capex-to-Operating-Cash-Flow

China NT Pharma Group Co (HKSE:01011) Capex-to-Operating-Cash-Flow : 0.00 (As of Dec. 2024)


View and export this data going back to 2011. Start your Free Trial

What is China NT Pharma Group Co Capex-to-Operating-Cash-Flow?

Capex-to-Operating-Cash-Flow assesses how much of a company’s cash flow from operations is being devoted to capital expenditure. It’s also useful to distinguish whether the company is capital intensive or not.

China NT Pharma Group Co's Capital Expenditure for the six months ended in Dec. 2024 was HK$0.00 Mil. Its Cash Flow from Operations for the six months ended in Dec. 2024 was HK$-3.55 Mil.

GuruFocus do not calculate Capex-to-Operating-Cash-Flow if the Cash Flow from Operations is negative.


China NT Pharma Group Co Capex-to-Operating-Cash-Flow Historical Data

The historical data trend for China NT Pharma Group Co's Capex-to-Operating-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

China NT Pharma Group Co Capex-to-Operating-Cash-Flow Chart

China NT Pharma Group Co Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Capex-to-Operating-Cash-Flow
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.91 - 0.12 0.26 -

China NT Pharma Group Co Semi-Annual Data
Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Capex-to-Operating-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of China NT Pharma Group Co's Capex-to-Operating-Cash-Flow

For the Drug Manufacturers - Specialty & Generic subindustry, China NT Pharma Group Co's Capex-to-Operating-Cash-Flow, along with its competitors' market caps and Capex-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


China NT Pharma Group Co's Capex-to-Operating-Cash-Flow Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, China NT Pharma Group Co's Capex-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where China NT Pharma Group Co's Capex-to-Operating-Cash-Flow falls into.


;
;

China NT Pharma Group Co Capex-to-Operating-Cash-Flow Calculation

China NT Pharma Group Co's Capex-to-Operating-Cash-Flow for the fiscal year that ended in Dec. 2024 is calculated as

Capex-to-Operating-Cash-Flow=- Capital Expenditure / Cash Flow from Operations
=- (-0.19) / -9.68
=N/A

China NT Pharma Group Co's Capex-to-Operating-Cash-Flow for the quarter that ended in Dec. 2024 is calculated as

Capex-to-Operating-Cash-Flow=- Capital Expenditure / Cash Flow from Operations
=- (0) / -3.55
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


China NT Pharma Group Co  (HKSE:01011) Capex-to-Operating-Cash-Flow Explanation

Capex-to-Operating-Cash-Flow ratio assesses how much of a company’s Cash Flow from Operations is being devoted to Capital Expenditure. It is a good indicator in terms of how much the company is focused on growth. In general, a high Capex-to-Operating-Cash-Flow ratio indicates that the company is investing more in physical assets and is focused on growth and expansion. Conversely, lower ratio could indicate that a company has reached maturity and is no longer pursuing aggressive growth.

Moreover, the ratio is also useful to distinguish whether the company is capital intensive or not. If the ratio is large, then the company tends to be capital intensive. Lower ratio suggests that it’s a capital-light business. The ratio can be combined with ROIC % to identify whether the company is an asset-light business that has a high return on invested capital. This is one question investors commonly ask to see if a company qualifies as a good company.


China NT Pharma Group Co Capex-to-Operating-Cash-Flow Related Terms

Thank you for viewing the detailed overview of China NT Pharma Group Co's Capex-to-Operating-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


China NT Pharma Group Co Business Description

Traded in Other Exchanges
N/A
Address
198 Wellington Street, 28th Floor, The Wellington, Sheung Wan, Hong Kong, HKG
China NT Pharma Group Co Ltd is a technology-based pharmaceutical company. It is engaged in research and development, production, and sale of private-label drugs, as well as the provision of pharmaceutical marketing and promotion services in China. It focused on the research, development, production, and sales of orthopedic, psychiatric, and oncology drugs. The company operates in a single segment of Proprietary product production and sales. The company earns the majority of its revenue from the domestic market. The Group's revenue from an external customer was derived solely from its operations in the PRC.
Executives
Ieong Chong Mang
Golden Base Investment Limited
Wang Minzhi 2101 Beneficial owner
Shum Ning
Chin Yu
Ng Tit
Ieong Iat 2101 Beneficial owner

China NT Pharma Group Co Headlines

No Headlines